Cost-Effectiveness Analysis of Adding Daratumumab to Bortezomib, Melphalan, and Prednisone for Untreated Multiple Myeloma

Background: To evaluate the cost-effectiveness of adding daratumumab to bortezomib, melphalan, and prednisone for transplant-ineligible newly diagnosed multiple myeloma patients. Methods: A three-state Markov model was developed from the perspective of US payers to simulate the disease development o...

Descripción completa

Detalles Bibliográficos
Autores principales: Cao, Yaohua, Zhao, Lina, Zhang, Tiantian, Cao, Weiling
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7957051/
https://www.ncbi.nlm.nih.gov/pubmed/33732154
http://dx.doi.org/10.3389/fphar.2021.608685

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7957051/
https://www.ncbi.nlm.nih.gov/pubmed/33732154
http://dx.doi.org/10.3389/fphar.2021.608685

Ejemplares similares